The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | TAGS: trifluridine/tipiracil in metastatic gastric adenocarcinoma
Michele Ghidini, MD, PhD, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Milan, Italy, provides an overview of the TAGS study (NCT02500043), a randomized Phase III trial in which patients with metastatic gastric adenocarcinoma were treated with oral trifluridine/tipiracil plus best supportive care or placebo plus best supportive care. Trifluridine/tipiracil was found to significantly improve overall survival compared with placebo and was well tolerated in this heavily pretreated population of patients with advanced gastric cancer; combination trifluridine/tipiracil could represent a new treatment approach in this population who represent a high unmet medical need. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
